TY - JOUR
T1 - VPAC1 targeted 64Cu-TP3805 positron emission tomography imaging of prostate cancer
T2 - Preliminary evaluation in man
AU - Tripathi, Sushil
AU - Trabulsi, Edouard J.
AU - Gomella, Leonard
AU - Kim, Sung
AU - McCue, Peter
AU - Intenzo, Charles
AU - Birbe, Ruth
AU - Gandhe, Ashish
AU - Kumar, Pardeep
AU - Thakur, Mathew
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Objective To evaluate 64Cu-TP3805 as a novel biomolecule, to positron emission tomography (PET) image prostate cancer (PC), at the onset of which VPAC1, the superfamily of G protein-coupled receptors, is expressed in high density on PC cells, but not on normal cells. Materials and Methods Twenty-five patients undergoing radical prostatectomy were PET/X-ray computerized tomography imaged preoperatively with 64Cu-TP3805. Standardized maximum uptake (SUVmax) values were determined and malignant lesions (standardized uptake value > 1.0) counted, and compared with histologic findings. Whole-mount pathology slides from 6 VPAC1 PET imaged patients, 3 benign prostatic hyperplasia patients, 1 malignant and 1 benign lymph node underwent digital autoradiography (DAR) after 64Cu-TP3805 incubation and were compared to hematoxylin- and eosin-stained slides. Results In 25 patients who underwent PET imaging, 212 prostate gland lesions had SUVmax > 1.0 vs 127 lesions identified by histology of biopsy tissues. The status of the additional 85 PET identified prostate lesions remains to be determined. In 68 histologic slides from 6 PET imaged patients, DAR identified 105 of 107 PC foci, 19 of 19 high-grade prostatic intraepithelial neoplasias, and ejaculatory ducts and verumontanum involved with cancer. Additionally, DAR found 9 PC lesions not previously identified histologically. The positive and negative lymph nodes were correctly identified, and in 3 of 3 benign prostatic hyperplasia patients and 5 of 5 cysts, DAR was negative. Conclusion This feasibility study demonstrated that 64Cu-TP3805 delineates PC in vivo and ex vivo, provided normal images for benign masses, and is worthy of further studies.
AB - Objective To evaluate 64Cu-TP3805 as a novel biomolecule, to positron emission tomography (PET) image prostate cancer (PC), at the onset of which VPAC1, the superfamily of G protein-coupled receptors, is expressed in high density on PC cells, but not on normal cells. Materials and Methods Twenty-five patients undergoing radical prostatectomy were PET/X-ray computerized tomography imaged preoperatively with 64Cu-TP3805. Standardized maximum uptake (SUVmax) values were determined and malignant lesions (standardized uptake value > 1.0) counted, and compared with histologic findings. Whole-mount pathology slides from 6 VPAC1 PET imaged patients, 3 benign prostatic hyperplasia patients, 1 malignant and 1 benign lymph node underwent digital autoradiography (DAR) after 64Cu-TP3805 incubation and were compared to hematoxylin- and eosin-stained slides. Results In 25 patients who underwent PET imaging, 212 prostate gland lesions had SUVmax > 1.0 vs 127 lesions identified by histology of biopsy tissues. The status of the additional 85 PET identified prostate lesions remains to be determined. In 68 histologic slides from 6 PET imaged patients, DAR identified 105 of 107 PC foci, 19 of 19 high-grade prostatic intraepithelial neoplasias, and ejaculatory ducts and verumontanum involved with cancer. Additionally, DAR found 9 PC lesions not previously identified histologically. The positive and negative lymph nodes were correctly identified, and in 3 of 3 benign prostatic hyperplasia patients and 5 of 5 cysts, DAR was negative. Conclusion This feasibility study demonstrated that 64Cu-TP3805 delineates PC in vivo and ex vivo, provided normal images for benign masses, and is worthy of further studies.
KW - Adult
KW - Aged
KW - Coordination Complexes
KW - Feasibility Studies
KW - Humans
KW - Male
KW - Middle Aged
KW - Peptides
KW - Positron-Emission Tomography
KW - Prostatic Hyperplasia
KW - Prostatic Neoplasms/diagnostic imaging
KW - Receptors, Vasoactive Intestinal Polypeptide, Type I/biosynthesis
UR - http://www.scopus.com/inward/record.url?scp=84960367318&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2015.10.012
DO - 10.1016/j.urology.2015.10.012
M3 - Article
C2 - 26519886
AN - SCOPUS:84960367318
SN - 0090-4295
VL - 88
SP - 111
EP - 118
JO - Urology
JF - Urology
ER -